20Jan 2017

ENDOTHELIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS-ROLE OF SYSTEMIC INFLAMMATION ,TRADITIONAL CVD RISK FACTORS IN ENDOTHELIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS.

  • Director Pri-Med Care ,Texas USA. Principal ,RGCP,India
Crossref Cited-by Linking logo
  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Rheumatoid Arthritis (RA), is a inflammatory joint disease of chronic nature with predominant articular symptoms of pain ,swelling and stiffness.The most common extraarticular manifestation is cardiovascular disease which accounts for 50 % mortality in RA patients . Complex interplay between traditional CVD risk factors ,systemic inflammation and vascular function in RA are the reasons behind the scene worse outcome in RA patients .5 The MCC of mortality in Rheumatoid Arthritis patients is cardiovascular disease .1,2 Endothelial dysfunction is directly related to RA associated systemic inflammation The aim of the review is to discuss Endothelium ,its morphology and normal physiology ,consider endothelial dysfunction (ED ) in RA patients and relate endothelial dysfunction to systemic inflammation and traditional CVD risk factors and also consider the effect of drugs on vascular function.


  1. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(5):607-13.
  2. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. American Journal of Cardiology 2002; 89 (suppl):33D-8D.
  3. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46(8):2010-9.
  4. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26(12):2562-71. 175
  5. Del Rincon I, Freeman GL, Haas RW, O\'Leary DH, Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005; 52(11):3413-23.
  6. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005; 7(7):1-24.180
  7. Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 2002; 1(6):338-47.
  8. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. ClinSci (Lond) 2000; 98(5):531-5.
  9. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti- Tumor Necrosis Factor-{alpha} Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis. Circulation 2002; 106(17):2184-7.
  10. Datta D, Ferrell WR, Sturrock RD, Jadhav ST, Sattar N. Inflammatory suppression rapidly attenuates microvascular dysfunction in rheumatoid arthritis. Atherosclerosis 2007; 192(2):391-5.
  11. Galley HF, Webster NR. Physiology of the endothelium. Br J Anaesth 2004; 93(1):105-13.
  12. Lerman A, ZeiherAM. Endothelial Function: Cardiac Events. Circulation 2005; 111(3):363-8.
  13. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52(3):722-32.
  14. Rhodin JAG. Architecture of the vessel wall. In: Bohr DF, Somlyo AP, Sparks JR HV, Gieger SR, editors. Handbook of Physiology: The Cardiovascular System. The Williams and Wilkins Company; 1980. p. 1-31. 188
  15. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789):373-6.
  16. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2(8670):997-1000.
  17. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 2000; 6(12):1362-7.
  18. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 2006; 147 Suppl 1:S193-S201.
  19. Kuvin JT, Patel AR, Karas RH. Need for standardization of noninvasive assessment of vascular endothelial function. Am Heart J 2001; 141(3):327-8.
  20. Kubli S, Waeber B, le-Ave A, Feihl F. Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J CardiovascPharmacol 2000; 36(5):640-8.
  21. Jadhav S, Sattar N, Petrie JR, Cobbe SM, Ferrell WR. Reproducibility and repeatability of peripheral microvascular assessment using iontophoresis in conjunction with laser Doppler imaging. J CardiovascPharmacol 2007; 50(3):343- 9.
  22. Ramsay JE, Ferrell WR, Greer IA, Sattar N. Factors critical to iontophoretic assessment of vascular reactivity: implications for clinical studies of endothelial dysfunction. J CardiovascPharmacol 2002; 39(1):9-17.
  23. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35(1):8-17.
  24. Haskard DO. Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol 2004; 33(5):281-92.
  25. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(5):607-13.
  26. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. American Journal of Cardiology 2002; 89 (suppl):33D-8D.
  27. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. ClinSci (Lond) 2000; 98(5):531-5.
  28. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how \"high-grade\" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108(24):2957-63.
  29. Leoncini G, Viazzi F, Parodi D, Ratto E, Vettoretti S, Vaccaro V, et al. Mild Renal Dysfunction and Cardiovascular Risk in Hypertensive Patients. J Am SocNephrol 2004; 15(90010):S88-S90.
  30. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89(9):763-71.
  31. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis and Rheumatism 2003; 48(1):81-9.
  32. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti- Tumor Necrosis Factor-{alpha} Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis. Circulation 2002; 106(17):2184-7.
  33. Bergholm R, Leirisalo-Repo M, Vehkavaara S, Makimattila S, Taskinen MR, Yki- Jarvinen H. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. ArterioThrombVascBiol 2002; 22(10):1637-41.
  34. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004; 63(1):31-5. 205
  35. VanDoornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003; 48(1):72-80.
  36. Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. ActaClinBelg 2007; 62(4):218-22. 206
  37. Maini R, Feldman M. Immunopathogenesis of Rheumatoid Arthritis. Oxford Textbook of Rheumatology.2nd ed. 1998. p. 983-1004.
  38. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996; 39(5):732-5.
  39. Wallberg-Jonsson S, Caidahl K, Klintland N, Nyberg G, Rantapaa-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in longstanding rheumatoid arthritis. Scand J Rheumatol 2008; 37(1):1-5.
  40. Crilly MA, Kumar V, Clark HJ, Scott NW, Macdonald AG, Williams DJ. Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a doseresponse relationship independent of established cardiovascular risk factors. Rheumatology (Oxford) 2009.
  41. Kumeda Y, Inaba M, Goto H, Nagata M, Henmi Y, Furumitsu Y, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients withrheumatoid Arthritis Rheum 2002; 46(6):1489-97.
  42. Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002; 46(7):1714-9.
  43. Ciftci O, Yilmaz S, Topcu S, CalIskan M, Gullu H, Erdogan D, et al. Impaired coronary microvascular function and increased intima-media thickness in rheumatoid arthritis. Atherosclerosis 2008; 198(2):332-7.
  44. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans. Circulation 2000; 102(9):994-9.
  45. Arosio E, De MS, Rigoni A, Prior M, Delva P, Lechi A. Forearm haemodynamics, arterial stiffness and microcirculatory reactivity in rheumatoid arthritis. J Hypertens 2007; 25(6):1273-8.
  46. Cardillo C, Schinzari F, Mores N, Mettimano M, Melina D, Zoli A, et al. Intravascular tumor necrosis factor [alpha] blockade reverses endothelial dysfunction in rheumatoid arthritis[ast]. ClinPharmacolTher 2006; 80(3):275-81.
  47. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, StenlundH,et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48(10):2741-9.
  48. Cotran RS, Kumar V, Collins T. Pathologic Basis of Disease. Philadelphia, USA: W.B. Saunders Company; 1999.
  49. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54(1):38-46.
  50. Veldhuijzen van Zanten JJ, Kitas GD. Inflammation, carotid intima-media thickness and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2008; 10(1):102.
  51. Hannawi S, Haluska B, Marwick TH, Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007; 9(6):R116.
  52. Schott LL, Kao AH, Cunningham A, Wildman RP, Kuller LH, Sutton-Tyrrell K, et al.Do carotid artery diameters manifest early evidence of atherosclerosis in womenwith rheumatoid arthritis? J Womens Health (Larchmt ) 2009; 18(1):21-9.
  53. Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, et al. Utility ofthe Framingham risk score to predict the presence of coronary atherosclerosis inpatients with rheumatoid arthritis. Arthritis Res Ther 2006; 8(6):R186.
  54. Scognamiglio R, Negut C, de Kreutzenberg SV, Tiengo A, Avogaro A. Postprandialmyocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation2005; 112(2):179-84.
  55. Stokes KY, Granger DN. The microcirculation: a motor for the systemicinflammatory response and large vessel disease induced byhypercholesterolaemia? J Physiol 2005; 562(Pt 3):647-53.
  56. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE, et al.Smooth muscle dysfunction occurs independently of impaired endotheliumdependentdilation in adults at risk of atherosclerosis. J Am CollCardiol 1998;32(1):123-7.
  57. Ghiadoni L, Magagna A, Kardasz I, Taddei S, Salvetti A. Fixed Dose Combinationof Perindopril and IndapamideImproves Peripheral Vascular Function in EssentialHypertensive Patients. Am J Hypertens 2009; 22(5):506-12.
  58. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, NevillAM,Koutedakis Y, et al. Association of physical inactivity with increased cardiovascularrisk in patients with rheumatoid arthritis. Eur J CardiovascPrevRehabil 2009;16(2):188-94.
  59. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Sandoo A, Toms TE, NevillAM, et al. Rheumatoid cachexia and cardiovascular disease.ClinExpRheumatol2009; 27(6):985-8.
  60. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, LlorcaJ,Vidan J, et al. HLA-DRB1 status affects endothelial function in treated patients withrheumatoid arthritis. The American Journal of Medicine 2003; 114(8):647-52.
  61. John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in earlyrheumatoid arthritis. Best Pract Res ClinRheumatol 2009; 23(1):71-82.
  62. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapyassociates with reduced prevalence of the metabolic syndrome in rheumatoidarthritis patients over the age of 60- more than just an anti-inflammatory effect? Across sectional study. Arthritis Res Ther 2009; 11(4):R110.
  63. Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, KaplanoglouT, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricularfunction in patients with rheumatoid arthritis.Circulation 2008; 117(20):2662-9.
  64. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, az-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA. Short-term improvement of endothelial function inrituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factoralpha blocker therapy. Arthritis Rheum 2008; 59(12):1821-4.
  65. Syngle A, Vohra K, Kaur L, Sharma S. Effect of spironolactone on endothelialdysfunction in rheumatoid arthritis. Scand J Rheumatol 2009; 38(1):15-22.
  66. Banks M, Flint J, Bacon PA, Kitas GD. Rheumatoid arthritis is an independent riskfactor for ischaemic heat disease [abstract]. Arthritis and Rheumatism 2000; 43(suppl. 9):S385.
  67. Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, et al. Effects of Long-Term Disease-Modifying Antirheumatic Drugs on Endothelial Function in Patientswith Early Rheumatoid Arthritis. CardiovascTher 2010.
  68. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, CamiciPG.Chronic inflammation and coronary microvascular dysfunction in patientswithoutrisk factors for coronary artery disease. Eur Heart J 2009; 30(15):1837-43.
  69. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilatordysfunction on adverse long-term outcome of coronary heart disease. Circulation2000; 101(16):1899-906.
  70. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., LermanA.Long-term follow-up of patients with mild coronary artery disease and endothelialdysfunction. Circulation 2000; 101(9):948-54.
  71. Gokce N, Keaney JF, Jr., Hunter LM, Watkins MT, Nedeljkovic ZS, MenzoianJO,et al. Predictive value of noninvasively determined endothelial dysfunction for longtermcardiovascular events in patients with peripheral vascular disease. J Am CollCardiol 2003; 41(10):1769-75.
  72. Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L, et al. Endothelialdysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysisusing imaging techniques and laboratory markers of inflammation andautoimmunity. J Rheumatol 2008; 35(3):398-406.
  73. Rojas-Villarraga A, Ortega-Hernandez OD, Gomez LF, Pardo AL, L≤pez-GuzmβnS, rango-Ferreira C, et al. Risk Factors Associated with Different Stages ofAtherosclerosis in Colombian Patients with Rheumatoid Arthritis. Seminars inArthritis and Rheumatism 2008; In Press, Corrected Proof.
  74. Aziz M, Yadav KS. Atherosclerosis: An extra articular manifestation of Rheumatoid Arthritis AnnClin Lab Res. 2016, 4: 4.
  75. Aziz M, Yadav KS. Pathogenesis of Atherosclerosis. Med Clin Rev. 2016, 2:3.

[Maria Aziz and K.S Yadav. (2017); ENDOTHELIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS-ROLE OF SYSTEMIC INFLAMMATION ,TRADITIONAL CVD RISK FACTORS IN ENDOTHELIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS. Int. J. of Adv. Res. 5 (1). 223-231] (ISSN 2320-5407). www.journalijar.com


Dr Maria Aziz
Director Pri-Med Care ,Texas USA

DOI:


Article DOI: 10.21474/IJAR01/2742       DOI URL: http://dx.doi.org/10.21474/IJAR01/2742


Share this article